SV2A Density Cannabis Use Disorder

Eligibility Criteria

• 1. Able to provide informed consent
• 2. Male and female 18-75 years old
• 3. Daily cannabis use
• 4. Positive urine screen for cannabinoids and negative for all other drugs on
• 5. Diagnosis of DSM-5 cannabis use disorder (≥ moderate, i.e., ≥ 4 \[of 11\] symptoms).
• 6. Must express a willingness at screening to set a date to attempt to quit using cannabis.
• 7. Physically healthy i.e., no clinically unstable medical conditions.
• 8. For women of childbearing potential (WOCBP) and men, willingness to practice birth control and to inform study staff immediately if either they (for women) or their partner (for men) becomes pregnant.
• 9. Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.
• 1. Laboratory tests with clinically significant abnormalities or positive urine toxicology screen with exception of cannabinoids.
• 2. Women with a positive pregnancy test or women who are lactating.
• 3. Have implanted or embedded metal objects or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist) in such a way that might have led to unknown, indwelling metal fragments that could cause injury if they moved in response to placement in the magnetic field
• 4. Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.
• 5. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) Subjects who have donated blood within 8 weeks of the present study
• 6. Medications that could alter synaptic density and, therefore, confound the interpretation of study data.
• 7. Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.